https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and?utm_campaign=New%20FDA%20Drug%20Safety%20Communication%20on%20tofacitinib%20-%20Drug%20Information%20Update&utm_medium=email&utm_source=Eloqua
There is a position open in my area. Is it a backfill. I am guessing that based on what I’m seeing. Is there a team that sells Xaljenz only? I applied before I saw this. Serious relies on thoughts please?
Face it, it's over for us. Abbvie's JAK will take over the oral RA business. We are just too toxic, too inconvenient and all these years later we still have zero managed care access.
Payer Access " nationally" is decent now. The Culture went toxic & downhill with Primary Care mindset FAST when they doubled the reps & tripled the managers with Primary Care hires. Culture has been dummied down to non thinking activity metrics now. Abbvie JAK is not better but equal to Xeljanz so it will come down to who has better coverage and that will be Abvvie in Jan. New VP sales has zero sales experience and a "unique special" relationship with the Nebraska DM, that is widely known throughout the reps. His experiences did not qualify for a VP of Sales job. There were a lot more qualified VP candidates in I&I but there was not any posting or interviewing process . JUST a placement.
